reports
- GlobalData Department
Orexigen Therapeutics Inc (OREX) - Pharmaceuticals & Healthcare - Deal...
Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, t...
- Maxim Jacobs
Contrave comeback
Orexigen’s decision to shift its US marketing focus from healthcare providers to consumers appears to be paying dividends as there has been a significant rebound in Contrave prescriptions since the launch of the patient-centric campaign. Outside of the US, progress continues as the product has launched in 13 countries, with another 10 expected by the end of the year, including Italy, where Orexigen just signed a local commercial and distribution partner.
Update: Taking control of Contrave
On 15 March Orexigen announced the acquisition of US distribution rights to its obesity treatment Contrave from Takeda. The company simultaneously announced a new collaboration with Valeant for the commercialization of Mysimba (Contrave ex-US) in 18 Central and Eastern European countries. We value Orexigen at $213m, significantly reduced from $1.09bn, mainly on reduced expectations for Contrave in the US. However, our fair value of $1.47/share is substantially above the current $0.51 share price...
Initiation: Contrave - leading branded weight loss medicine
There is reason to be optimistic about Contrave after its progress vs competitors following launch just over one year ago and the backing of a dedicated salesforce of 900, through partner Takeda, selling into a massive potential market. Contrave was approved in the EU in March and recently signed a commercialization agreement with Kwang Dong in South Korea, communicating its ex-US strategy in its Q3 conference call whereby it plans a territory-by-territory approach. On our analysis, the strong p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.